Immuno-oncology company with innovative approach to addressing hard-to-treat cancers via ‘de-inhibition’ of the immuno-suppressive tumour microenvironment:
"Surface is developing multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust immunologic response and enhance outcomes for patients with cancer.
Surface’s pipeline spans compelling areas of discovery and development across four key areas of immune modulators to: activate both macrophages and natural killer cells, inhibit or deplete regulatory T cells and block suppressive cell signaling molecules, including cytokines and metabolites."
GSK have displayed strong interest in acquisition in the near to mid term, suggesting this stock has considerable upside potential in the next 1-2 years.